Phase 3 N=7,576 Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Breast Cancer
Primary: Event-free Survival — 88; 89 percentage of participants — p=0.85
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=37 Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.
Wilson's Disease
Primary: Safety and Efficacy — 37 participants
N/A N=35 Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)
Paraplegia · Quadriplegia · Spinal Cord Injury
Primary: Cardiovascular Fitness as Determined by Lokomat Peak VO2 Assessments — 20.2; 12.9; 22.5; 11.6 ml/kg/min
N/A N=1,228 The Effects of Aspirin in Gestation and Reproduction
Birth · Spontaneous Abortion
Primary: Live Birth — 309; 286 livebirths — p=0.0984
Phase 3 N=558 A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1 — -0.23; -0.58; -0.77; -0.89 Percent — p=0.0207
Phase 4 N=169 D-Cycloserine Enhancement of Exposure in Social Phobia
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 39.19; 42.44 units on a scale
Phase 3 N=5,407 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause…
Phase 3 N=433 Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Meningococcal Meningitis
Primary: Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Titers ≥ 1:8 Directed Against N. Meningitidis Serogroups A, C, W-135, and Y — 10; 35; 2; 34…
Phase 2 N=65 A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension
Type 2 Diabetes Mellitus
Primary: Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population — 125.6; 147220.2 pg*h/mL
Phase 3 N=67 Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes
Pregnancy
Primary: Heart Rate — 146.0; 145.2; 142.5; 140.8 Beats per minute
N/A N=20 Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism
Primary: The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours — 40.6; 46.2; 39.8; 58.8 pg/ml — p=0.1
Phase 3 N=192 Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
Japanese Encephalitis
Primary: Geometric Mean Titer (GMT) at Day 56 for Anti-JEV Neutralizing Antibodies — 192.2; 202.7 titers — p=<0.0001
Phase 4 N=46 Cilostazol Augmentation Study in Dementia
Alzheimer's Dementia
Primary: Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method — 81.70; 80.40; 84.60; 81.33 Bq/Bq (no unit) — p=0.14
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
Phase 3 N=3,057 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period — 15.06; 24.37 Percentage of events/patients…